Promising Results from Antibody-Drug Conjugate in Treating Rare Blood Cancer
A novel antibody-drug conjugate shows high response rates and safety in treating the rare and aggressive blood cancer BPDCN, potentially offering a new standard of care.
A recent study has showcased encouraging safety profiles and response rates of a novel antibody-drug conjugate (ADC), pivekimab sunirine (PVEK), in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Led by researchers at The University of Texas MD Anderson Cancer Center, the Phase I/II trial demonstrated significant efficacy, especially in newly diagnosed patients. Out of 33 newly diagnosed BPDCN cases, the treatment achieved an overall response rate of 85%, with 70% achieving complete remission and a median overall survival of approximately 16.6 months.
BPDCN is a rare, aggressive blood cancer that often involves the skin, bone marrow, and lymph nodes, and currently has limited therapeutic options. The study data, presented at the 2025 ASCO Annual Meeting, suggest that PVEK might soon become a new standard of care. Compared to the existing treatment, tagraxofusp-erzs—which targets the CD123 protein present on BPDCN cells—PVEK offers a targeted approach by delivering cytotoxic drugs directly to cancer cells, leading to their death.
The global multi-center trial enrolled 84 adult patients with CD123-positive BPDCN, including both newly diagnosed and relapsed/refractory cases. Participants received the treatment intravenously every 21 days on an outpatient basis. The most common side effect was reversible peripheral edema, which was manageable.
Researchers are optimistic about the potential of combining PVEK with other therapies to enhance treatment outcomes further. The trial received support from pharmaceutical company AbbVie, with researchers also serving on advisory boards and as consultants.
Overall, these promising results indicate that PVEK could revolutionize treatment strategies for BPDCN, offering hope for improved patient outcomes in this challenging disease.
Source: https://medicalxpress.com/news/2025-06-antibody-drug-conjugate-safety-response.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Cancer Drug Developed with Supercomputing and AI Successfully Halts Tumor Growth Without Toxic Side Effects
A new cancer drug developed through supercomputing and AI techniques effectively blocks tumor growth without toxic side effects, marking a major breakthrough in cancer therapy research.
Emerging Bacterial Vaccine Shows Promise in Early Human Trials
A new vaccine targeting group B meningococcus shows promising immune responses in early-stage human trials, paving the way for broader protection against bacterial meningococcal disease.
Innovative Model for Myelodysplastic Syndromes Reveals Key Genetic Changes Better Characterizing the Disease
A groundbreaking study enhances understanding of myelodysplastic syndromes by defining key genetic and chromosomal alterations using advanced genomic tools, supporting drug development efforts.
Innovative 3D-Printed Tumor Models Enhance Surgical Imaging Techniques
Texas Tech researchers have developed 3D-printed tumor models that replicate human tissue, aiming to refine surgical imaging techniques and improve tumor removal accuracy.